Frequently Asked Questions
We will impact the quality of healthcare in Africa by increasing access to genomic data from African populations to promote inclusive research and development, which will lead to:
- optimized treatment and diagnostic outcomes for the African population
- power drug discoveries that will treat Africans, but also treat all people
Presently, most genomic data used for development research is from Europe, United Kingdom and North American, we want to address the fact that less than 3% of genomic data available is African and the need to include underrepresented racial and ethnic minorities research. Increasing access to genomic data from African populations can:
- improve the responsiveness of products to the health of African people
- power drug discoveries that can treat people of all races
We can measure our impact from the researchers and product development companies that partner with us, incorporating the existing data from our biobank.
Publications using our resources will be required to acknowledge the source of data, which would let us know 54gene is contributing to increased inclusion of genomic data from African populations.
Our goal at 54gene is to build genetic data sets that make landmark discoveries, a reality; significantly improving diversity of genomic data used for discovery, diagnosis and treatment of disease by increasing the availability and access to genomic data from African populations.
54gene is a health technology company.
54gene was founded to significantly improve the inclusion of African populations in genomics research leading to discovery, diagnosis and treatment that would be more responsive to African populations.
We collaborate with health and research institutions in African countries to conduct research to generate primary data and biospecimen.
We have a state-of-the-art biobank, which is a facility used to store biospecimen in the right conditions to retain quality for when it is needed for secondary use.
Our laboratory has modern equipment with skilled medical consultants and laboratorians to ensure the quality of the tests we conduct.
At present we are scoping and mapping needs against our capacities, and as a result are unable to open our laboratory to the public for research partnerships.
With proper informed consent given by the participants, we can share the collected data and biospecimen with researchers and development research organizations for discovery and knowledge generation, diagnosis and treatment solutions.
Shared samples are devoid of any information that can be used to identify the individuals from whom it was taken.
We manage our data in accordance with the regulations of the Data and Sample Access Committee.
The sharing of our data is based on the terms of a fully executed Material Transfer Agreement, that would have been endorsed by the National Health Research Ethics Committee.
In all instances, people who have contributed specimens to the 54gene biobank are able to ask to withdraw their samples and destroy such specimen, where there is still some stock left, 54gene will honor such requests.
54gene de-identifies, stores and adds genetic information to the samples. The samples are then aggregated in large cohorts or groups that provide statistical significance, something an individual or a few samples alone cannot provide. Companies developing therapeutics or diagnostic tests pay 54gene for their efforts to collect, de-identify and aggregate high quality genetic data.
54gene is open to collaborate with development research institutions within and outside of Africa. 54gene is interested in evaluating all partnership opportunities as they arise.
54gene is currently focused on genomic studies related to non-communicable diseases and infectious diseases. On the former, we are interested in studying and supporting development research in cancers, endocrine disorders, cardiovascular diseases, neurodegenerative diseases and sickle cell disease. For infectious diseases, we’re interested in areas that are highly prevalent in Africa such as: HIV, Malaria, Tuberculosis, Hepatitis B, Lassa Fever
The purpose of all biobanks is to provide access to data and biospecimen for secondary use by other researchers.
At 54gene we are open to support both academic and development research. When we are supporting development research, we do not sell data or biospecimen to the development research institutions like the pharmaceutical companies, but rather they would pay us for our efforts (the work we carry out to collect, curate and store data and biospecimen).
As part of our corporate social responsibility, we will ensure that whenever we collaborate with development research institutions, like the pharmaceutical companies, and we receive proceeds from their use of the data and biospecimen in our biobank, a reasonable proportion of such proceeds will be administered to support systems strengthening the institutions we collaborate with in each country as we want to add Africa to the innovation map.
A commercial biobank operates solely for the purposes of collecting, curating, storing and sharing of data and biospecimen with commercial and non-commercial entities. This may be for health or non-health related uses.
At 54gene we are interested in collaborating with commercial and non-commercial entities that are working to develop diagnostics and treatment solutions to improve human health.
At 54gene, our biobank resources – specimen and data are available for use by academic and development research institutions. A data and sample access committee will review and make decisions to provide access to data and samples based on availability and objectives of the proposed research use.At 54gene, our biobank resources – specimen and data are available for use by academic and development research institutions. A data and sample access committee will review and make decisions to provide access to data and samples based on availability and objectives of the proposed research use.
At 54gene, we only accept and biobank specimen for which we have the proper informed consent of the participant to bank. In our database, all biospecimen are matched against the consent received by the participant.
Research collaboration is an established professional endeavor. It entails a relationship between an organization that is providing the funding for research, institutions/communities in which the research will be conducted and the researchers that will conduct those studies.
People who are engaged as researchers receive remuneration for their efforts in planning and implementing the study at the sites assigned to them, which is usually the hospital where they are working.
In our biobank, each specimen is accompanied with some information about the person from whom the specimen was collected, but which cannot be used to tell who that person is.
The samples are stored in a de-identified manner in our biobank. A portion of the sample will have genetic information added and then the data is aggregated with tens of thousands of other samples.
In all instances, people who have contributed specimen to 54gene biobank are able to ask to withdraw their samples and destroy such biospecimen, where there is still some stock left. Any information derived from said sample is also deleted.
At 54gene, we only accept and biobank specimen for which we have the consent of the participant to bank. Our informed consent describes the use of samples for research. The consent terms and conditions refer to the samples being used in Nigeria or overseas. In our database, all biospecimen are matched against the consent received by the participant.
Genomics research is exploratory by nature and not interventional. For this reason it is difficult to have a direct correlation between genetics research and intervention.
The genomics research – drug discovery journey includes many interim discovery steps. Our research currently involves the earliest stages of the drug-discovery journey. Our data will be combined with many other sources of data and it is highly unlikely to attribute any discovery to such data.
We do not give or sell samples we have collected. In the event 54gene collaborates with a development research organisation and receives some proceeds for providing access to data with commercial purposes in mind, roughly 5 to 20 per cent of the profits from its research contracts with companies will go to a foundation in each country it operates in. Committees of eminent scientists and societal leaders will decide where the money goes.
If 54gene were to be involved in a research collaboration that leads to co-development of a new drug, we will work with all relevant parties to provide preferential access to such drugs for African countries.
Because of the nature of genomics research, there is no direct benefit to participants. However, there is a potential for long term benefit to society by ensuring inclusion of Africans in research and development of therapeutics.
Each person’s sample contributes to our biobank and as part of our corporate social responsibility, we will ensure benefit sharing takes place by utilising a portion of our proceeds for the benefit of the ecosystems with whom we partner. We will also drive up the knowledge economy in the host cities of our resource providers therefore adding Africa to the genomics innovation map.
We use a heavily secure, state of the art cloud architecture system. Even if our data is breached (which is very unlikely) all our data is fully encrypted, and will render it useless outside of our system. Reliable access control ensures that only authorized personnel has access to the information they require and we also keep a log of IP addresses that access our information. Multiple brute force access attempts will be flagged from external IPs which are then blocked.
No, we will not. At 54gene, we only accept and biobank specimens where we have received the full informed consent of the participant to biobank. In our database, all biospecimens are matched against the consent received by the participant.